Key Points
- Michael Jon Brown, DexCom's EVP, sold 1,700 shares on March 16 at an average price of $64.85 for $110,245, reducing his holding by 1.48% to 112,904 shares, according to an SEC filing.
- Earnings beat: DexCom reported $0.68 EPS vs. $0.65 expected and $1.26B revenue vs. $1.25B expected, with revenue up 13.1% year‑over‑year; analysts have an average rating of "Moderate Buy" and a $85.50 target.
- Shares traded up 0.5% to $68.03, the company has a market cap of about $26.2B and a PE of 32.34, a one‑year range of $54.11–$89.98, and roughly 97.75% of stock is held by institutional investors.
DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the sale, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This trade represents a 1.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
DexCom Stock Up 0.5%
Shares of DXCM traded up $0.37 during trading hours on Thursday, hitting $68.03. The company had a trading volume of 145,578 shares, compared to its average volume of 5,149,891. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $26.18 billion, a PE ratio of 32.34, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company's fifty day moving average price is $70.53 and its two-hundred day moving average price is $68.22.
DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm's quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.45 earnings per share. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.
Hedge Funds Weigh In On DexCom
Several hedge funds and other institutional investors have recently modified their holdings of DXCM. Trust Co. of Vermont boosted its stake in DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company's stock worth $74,000 after purchasing an additional 145 shares in the last quarter. CVA Family Office LLC increased its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. GAMMA Investing LLC increased its stake in DexCom by 2.5% during the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company's stock valued at $474,000 after purchasing an additional 169 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company's stock worth $61,000 after buying an additional 178 shares during the last quarter. Finally, Inspire Investing LLC lifted its stake in shares of DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company's stock worth $211,000 after buying an additional 180 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Weiss Ratings upgraded shares of DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Truist Financial restated a "buy" rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Robert W. Baird set a $87.00 price target on DexCom in a research report on Friday, February 13th. Piper Sandler reaffirmed an "overweight" rating on shares of DexCom in a research report on Thursday, February 5th. Finally, Mizuho increased their price objective on DexCom from $78.00 to $90.00 and gave the company an "outperform" rating in a report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $85.50.
Check Out Our Latest Stock Analysis on DXCM
About DexCom
(
Get Free Report)
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
